Q-omics provides the consensus-scored MAD2L1BP profile across patient tissues and cancer cell-line models. MAD2L1BP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAD2L1BP is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MAD2L1BP protein abundance shows 23,303 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where MAD2L1BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAD2L1BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAD2L1BP survival associations across molecular data types. MAD2L1BP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAD2L1BP RNA expression–survival associations across cancer types. High MAD2L1BP expression shows unfavorable associations in UVM, ACC, LIHC and KICH, but favorable associations in KIRC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAD2L1BP RNA expression.
This table summarizes MAD2L1BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MAD2L1BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAD2L1BP shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, KIRC, KIRP and LUAD. The HNSC box plot shows higher MAD2L1BP RNA expression in tumor versus normal tissue (log2 FC = +0.554, t-test p < 0.001).
This table shows molecular features associated with MAD2L1BP in patient tissues and cancer cell lines. In patient samples, MAD2L1BP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAD2L1BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
